SEGMENT REPORTING - Schedule of Operating Financial Results of Therapeutics Segment (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2025	Sep. 30, 2024
Revenues:
Total revenues	$ 118,697			$ 48,118			$ 299,692	$ 116,545
Operating expenses:
Research and development	16,284			12,128			46,287	36,513
General and administrative	108,633			57,910			296,641	168,280
Total operating expenses	133,226			73,280			362,685	212,693
Loss from operations before other income (expense)	(14,529)			(25,162)			(62,993)	(96,148)
Net loss	(12,585)	$ (20,340)	$ (25,120)	(23,420)	$ (33,290)	$ (35,731)	(58,045)	(92,441)
Other segment disclosures:
Interest income	4,114			4,120			11,797	11,367
Interest expense	(2,268)			(2,445)			(6,721)	(5,537)
Reportable Segment
Revenues:
Total revenues	118,697			48,118			299,692	116,545
Operating expenses:
Cost of sales	8,309			3,242			19,757	7,900
Research and development	16,284			12,128			46,287	36,513
Selling and marketing	64,708			35,543			190,851	95,681
General and administrative	43,925			22,367			105,790	72,599
Total operating expenses	133,226			73,280			362,685	212,693
Loss from operations before other income (expense)	(14,529)			(25,162)			(62,993)	(96,148)
Other reconciling items	1,944			1,742			4,948	3,707
Net loss	(12,585)			(23,420)			(58,045)	(92,441)
Other segment disclosures:
Interest income	4,114			4,120			11,797	11,367
Interest expense	(2,268)			(2,445)			(6,721)	(5,537)
Depreciation and amortization expense	460			284			1,373	793
Product sales, net
Revenues:
Total revenues	118,697			48,118			299,692	113,651
Operating expenses:
Cost of sales	8,309			3,242			19,757	7,900
Product sales, net | Reportable Segment
Revenues:
Total revenues	118,697			48,118			299,692	113,651
License fees and collaboration revenue
Revenues:
Total revenues	0			0			0	2,894
License fees and collaboration revenue | Reportable Segment
Revenues:
Total revenues	$ 0			$ 0			$ 0	$ 2,894